Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $18.3 million.

  • Lyell Immunopharma's Shares Outstanding (Diluted Average) rose 4255.17% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 4255.17%. This contributed to the annual value of $261.5 million for FY2024, which is 418.24% up from last year.
  • Latest data reveals that Lyell Immunopharma reported Shares Outstanding (Diluted Average) of $18.3 million as of Q3 2025, which was up 4255.17% from $14.8 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Shares Outstanding (Diluted Average) ranged from a high of $295.1 million in Q1 2025 and a low of $12.8 million during Q2 2024
  • Its 5-year average for Shares Outstanding (Diluted Average) is $173.3 million, with a median of $246.3 million in 2022.
  • In the last 5 years, Lyell Immunopharma's Shares Outstanding (Diluted Average) skyrocketed by 131372.16% in 2022 and then crashed by 9490.09% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Shares Outstanding (Diluted Average) (Quarter) stood at $135.9 million in 2021, then surged by 81.79% to $247.1 million in 2022, then increased by 1.58% to $251.0 million in 2023, then grew by 4.18% to $261.5 million in 2024, then crashed by 93.01% to $18.3 million in 2025.
  • Its last three reported values are $18.3 million in Q3 2025, $14.8 million for Q2 2025, and $295.1 million during Q1 2025.